Cardiff Oncology Inc
Company Profile
Business description
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Contact
11055 Flintkote Avenue
San DiegoCA92121
USAT: +1 858 952-7570
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
31
Stocks News & Analysis
stocks
Chart of the Week: AI proving a threat to company moats
stocks
ASX coal miners will benefit from higher prices
stocks
Nvidia earnings: Another stellar quarter with no signs of a slowdown
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,698.70 | 13.10 | -0.15% |
| CAC 40 | 7,969.88 | 4.61 | -0.06% |
| DAX 40 | 23,502.25 | 228.67 | -0.96% |
| Dow JONES (US) | 46,199.62 | 793.64 | -1.69% |
| FTSE 100 | 10,305.29 | 98.31 | -0.94% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,164.37 | 315.16 | -1.40% |
| Nikkei 225 | 53,734.88 | 1,504.52 | -2.72% |
| NZX 50 Index | 13,076.09 | 106.14 | -0.81% |
| S&P 500 | 6,626.82 | 89.27 | -1.33% |
| S&P/ASX 200 | 8,503.80 | 1.60 | -0.02% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |